Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.79
ARAY's Cash to Debt is ranked lower than
66% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 2.22 vs. ARAY: 0.79 )
Ranked among companies with meaningful Cash to Debt only.
ARAY' s Cash to Debt Range Over the Past 10 Years
Min: 0.72  Med: No Debt Max: No Debt
Current: 0.79
Equity to Asset 0.13
ARAY's Equity to Asset is ranked lower than
92% of the 288 Companies
in the Global Medical Devices industry.

( Industry Median: 0.62 vs. ARAY: 0.13 )
Ranked among companies with meaningful Equity to Asset only.
ARAY' s Equity to Asset Range Over the Past 10 Years
Min: -1.98  Med: 0.21 Max: 0.65
Current: 0.13
-1.98
0.65
Interest Coverage N/A
ARAY's Interest Coverage is ranked higher than
71% of the 223 Companies
in the Global Medical Devices industry.

( Industry Median: 76.81 vs. ARAY: N/A )
Ranked among companies with meaningful Interest Coverage only.
ARAY' s Interest Coverage Range Over the Past 10 Years
Min: 88.63  Med: N/A Max: N/A
Current: N/A
F-Score: 6
Z-Score: 0.46
M-Score: -2.90
WACC vs ROIC
8.69%
-6.84%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -1.22
ARAY's Operating margin (%) is ranked lower than
57% of the 299 Companies
in the Global Medical Devices industry.

( Industry Median: 2.72 vs. ARAY: -1.22 )
Ranked among companies with meaningful Operating margin (%) only.
ARAY' s Operating margin (%) Range Over the Past 10 Years
Min: -25.53  Med: -4.98 Max: 1.28
Current: -1.22
-25.53
1.28
Net-margin (%) -6.40
ARAY's Net-margin (%) is ranked lower than
61% of the 299 Companies
in the Global Medical Devices industry.

( Industry Median: 1.06 vs. ARAY: -6.40 )
Ranked among companies with meaningful Net-margin (%) only.
ARAY' s Net-margin (%) Range Over the Past 10 Years
Min: -32.67  Med: -8 Max: 2.56
Current: -6.4
-32.67
2.56
ROE (%) -39.51
ARAY's ROE (%) is ranked lower than
74% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 1.03 vs. ARAY: -39.51 )
Ranked among companies with meaningful ROE (%) only.
ARAY' s ROE (%) Range Over the Past 10 Years
Min: -68.25  Med: -29.53 Max: 4.2
Current: -39.51
-68.25
4.2
ROA (%) -5.40
ARAY's ROA (%) is ranked lower than
55% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: -0.43 vs. ARAY: -5.40 )
Ranked among companies with meaningful ROA (%) only.
ARAY' s ROA (%) Range Over the Past 10 Years
Min: -21.75  Med: -6.38 Max: 1.72
Current: -5.4
-21.75
1.72
ROC (Joel Greenblatt) (%) -7.92
ARAY's ROC (Joel Greenblatt) (%) is ranked lower than
55% of the 315 Companies
in the Global Medical Devices industry.

( Industry Median: 4.23 vs. ARAY: -7.92 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ARAY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -207.15  Med: -27.28 Max: 31.27
Current: -7.92
-207.15
31.27
Revenue Growth (3Y)(%) 4.70
ARAY's Revenue Growth (3Y)(%) is ranked higher than
54% of the 234 Companies
in the Global Medical Devices industry.

( Industry Median: 3.90 vs. ARAY: 4.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ARAY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -6.9  Med: 5.9 Max: 134.9
Current: 4.7
-6.9
134.9
EPS Growth (3Y)(%) -37.80
ARAY's EPS Growth (3Y)(%) is ranked lower than
89% of the 199 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. ARAY: -37.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ARAY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -37.8  Med: 6.8 Max: 91.3
Current: -37.8
-37.8
91.3
» ARAY's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-29)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

ARAY Guru Trades in Q3 2015

Steven Cohen 1,581,300 sh (New)
Jim Simons 1,996,723 sh (+76.60%)
Chuck Royce 2,153,500 sh (+7.81%)
PRIMECAP Management 8,603,700 sh (unchged)
Paul Tudor Jones 14,531 sh (-67.61%)
» More
Q4 2015

ARAY Guru Trades in Q4 2015

Steven Cohen 1,893,000 sh (+19.71%)
Paul Tudor Jones 17,001 sh (+17.00%)
Jim Simons 2,275,523 sh (+13.96%)
PRIMECAP Management 8,603,700 sh (unchged)
Chuck Royce 1,734,900 sh (-19.44%)
» More
Q1 2016

ARAY Guru Trades in Q1 2016

Jim Simons 2,781,400 sh (+22.23%)
Chuck Royce 1,999,500 sh (+15.25%)
Paul Tudor Jones Sold Out
PRIMECAP Management 8,544,500 sh (-0.69%)
Steven Cohen 1,640,800 sh (-13.32%)
» More
Q2 2016

ARAY Guru Trades in Q2 2016

Paul Tudor Jones 32,005 sh (New)
Jim Simons 3,319,000 sh (+19.33%)
PRIMECAP Management 8,523,000 sh (-0.25%)
Chuck Royce 1,722,000 sh (-13.88%)
Steven Cohen 110,100 sh (-93.29%)
» More
» Details

Insider Trades

Latest Guru Trades with ARAY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices
Compare:NAS:XENT, OTCPK:IPDQF, NAS:EXAC, OTCPK:MZRTF, NYSE:IVC, NAS:GNMK, NYSE:CRY, NAS:AXGN, OTCPK:SBMAF, NAS:ELOS, NAS:TNDM, OTCPK:VICA, NAS:KTWO, OTCPK:CSRMY, NAS:IRMD, NAS:RTIX, NAS:PAVM, NYSE:ITGR, AMEX:CVRS, NAS:IRIX » details
Traded in other countries:XEJ.Germany,
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise treatment solutions. Its products includes the CyberKnife Systems and the TomoTherapy Systems.

Accuray Inc was incorporated in California in 1990 and commenced operations in 1992. The Company was reincorporated in 2007 in Delaware. The Company is a radiation oncology company. It develops, manufactures, sells and supports precise treatment solutions. The Company's technologies are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy and image guided radiation therapy and adaptive radiation therapy. It operates in Europe, Middle East, India and Africa, Asia Pacific and Japan. Its suite of products includes the CyberKnife Systems and the TomoTherapy Systems. The CyberKnife Systems are fully robotic stereotactic radiosurgery systems, or SRS and stereotactic body radiation therapy systems, or SBRT used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimeter accuracy while patients breathe normally. Treatment with the CyberKnife Systems requires no anesthesia, and can be performed in one to five staged treatment sessions on an outpatient basis. In addition, the CyberKnife Systems are designed to minimize many of the risks and complications that are associated with other treatment options. The CyberKnife Systems include: the CyberKnife G4, which includes the Fixed collimator; CyberKnife VSI System, which includes the Fixed and Iris collimators and the new CyberKnife M6 Series System, that comes in configurations that have the option of Fixed collimator, Iris collimator, and a MultiLeaf collimator, or MLC. The TomoTherapy Systems are used to treat cancers and tumors, and enable efficient daily imaging to ensure the accuracy of the patient position before each treatment delivery. The TomoTherapy Systems operate on ring gantries and combine integrated CT imaging with intensity modulated radiation therapy or IMRT, which is designed to deliver radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The TomoTherapy Systems include the Hi-Art System, delivering CT-guided, helical IMRT; the TomoHD System, which includes both the TomoHelicalTM and TomoDirectTM treatment modalities and the Tomo H TM Series Systems that come in configuration options of TomoHTM, TomoHD and TomoHDATM and which includes one or more options such as TomoHelicalTM, TomoDirectTM, High Performance VoLo TM Planning and TomoEdge Dynamic Jaws. Its competitors are Elekta AB and Varian Medical Systems, Inc, Mitsubishi Heavy Industries, BrainLAB AG, and ViewRay Inc.

Ratios

vs
industry
vs
history
P/B 7.42
ARAY's P/B is ranked lower than
81% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 2.95 vs. ARAY: 7.42 )
Ranked among companies with meaningful P/B only.
ARAY' s P/B Range Over the Past 10 Years
Min: 1.1  Med: 3.35 Max: 11.51
Current: 7.42
1.1
11.51
P/S 1.11
ARAY's P/S is ranked higher than
78% of the 286 Companies
in the Global Medical Devices industry.

( Industry Median: 3.22 vs. ARAY: 1.11 )
Ranked among companies with meaningful P/S only.
ARAY' s P/S Range Over the Past 10 Years
Min: 0.8  Med: 1.59 Max: 6
Current: 1.11
0.8
6
PFCF 1096.00
ARAY's PFCF is ranked lower than
97% of the 101 Companies
in the Global Medical Devices industry.

( Industry Median: 29.21 vs. ARAY: 1096.00 )
Ranked among companies with meaningful PFCF only.
ARAY' s PFCF Range Over the Past 10 Years
Min: 15.71  Med: 39.7 Max: 1108
Current: 1096
15.71
1108
POCF 52.22
ARAY's POCF is ranked lower than
89% of the 131 Companies
in the Global Medical Devices industry.

( Industry Median: 21.00 vs. ARAY: 52.22 )
Ranked among companies with meaningful POCF only.
ARAY' s POCF Range Over the Past 10 Years
Min: 12.26  Med: 77.41 Max: 2124.44
Current: 52.22
12.26
2124.44
EV-to-EBITDA 36.53
ARAY's EV-to-EBITDA is ranked lower than
80% of the 171 Companies
in the Global Medical Devices industry.

( Industry Median: 17.64 vs. ARAY: 36.53 )
Ranked among companies with meaningful EV-to-EBITDA only.
ARAY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -666.8  Med: 25.85 Max: 1894.8
Current: 36.53
-666.8
1894.8
Current Ratio 1.72
ARAY's Current Ratio is ranked lower than
73% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 2.50 vs. ARAY: 1.72 )
Ranked among companies with meaningful Current Ratio only.
ARAY' s Current Ratio Range Over the Past 10 Years
Min: 0.94  Med: 1.77 Max: 2.75
Current: 1.72
0.94
2.75
Quick Ratio 1.17
ARAY's Quick Ratio is ranked lower than
74% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. ARAY: 1.17 )
Ranked among companies with meaningful Quick Ratio only.
ARAY' s Quick Ratio Range Over the Past 10 Years
Min: 0.78  Med: 1.46 Max: 2.43
Current: 1.17
0.78
2.43
Days Inventory 171.66
ARAY's Days Inventory is ranked lower than
66% of the 279 Companies
in the Global Medical Devices industry.

( Industry Median: 133.25 vs. ARAY: 171.66 )
Ranked among companies with meaningful Days Inventory only.
ARAY' s Days Inventory Range Over the Past 10 Years
Min: 70.63  Med: 128.43 Max: 199.92
Current: 171.66
70.63
199.92
Days Sales Outstanding 52.00
ARAY's Days Sales Outstanding is ranked higher than
74% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 68.07 vs. ARAY: 52.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
ARAY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 26.26  Med: 61.53 Max: 101.57
Current: 52
26.26
101.57
Days Payable 23.15
ARAY's Days Payable is ranked lower than
86% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 58.34 vs. ARAY: 23.15 )
Ranked among companies with meaningful Days Payable only.
ARAY' s Days Payable Range Over the Past 10 Years
Min: 20.39  Med: 29.32 Max: 122.61
Current: 23.15
20.39
122.61

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.80
ARAY's 3-Year Average Share Buyback Ratio is ranked higher than
55% of the 211 Companies
in the Global Medical Devices industry.

( Industry Median: -3.40 vs. ARAY: -2.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ARAY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -66.2  Med: -8.55 Max: -2.8
Current: -2.8
-66.2
-2.8

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.70
ARAY's Price/Median PS Value is ranked higher than
80% of the 261 Companies
in the Global Medical Devices industry.

( Industry Median: 1.02 vs. ARAY: 0.70 )
Ranked among companies with meaningful Price/Median PS Value only.
ARAY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.66  Med: 1.07 Max: 3.05
Current: 0.7
0.66
3.05
Earnings Yield (Greenblatt) (%) -0.99
ARAY's Earnings Yield (Greenblatt) (%) is ranked lower than
54% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 0.60 vs. ARAY: -0.99 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ARAY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -1  Med: 0.8 Max: 2.9
Current: -0.99
-1
2.9

More Statistics

Revenue (TTM) (Mil) $398.8
EPS (TTM) $ -0.32
Beta1.49
Short Percentage of Float13.76%
52-Week Range $4.75 - 7.54
Shares Outstanding (Mil)81.57

Analyst Estimate

Jun17
Revenue (Mil $)
EPS ($) -0.22
EPS w/o NRI ($) -0.22
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for ARAY

Headlines

Articles On GuruFocus.com
PRIMECAP Sells Portions of 3 Stakes Aug 03 2016 
Context Capital Management's Top Buys in Q2 2015 Jul 15 2015 
Vycor Value Could be Unlocked with These Major Partnerships Dec 05 2014 
Weekly CEO Buys Highlight: SONS, OPK, AKS, ARAY, ENH Nov 09 2014 
Weekly CEO Buys Highlight: JMP, SONS, OPK, ARAY, CBNJ Nov 04 2014 
Accuray: Leading the Field Of Radiosurgery Jul 24 2014 
Weekly CEO Buys Highlight: AGNC, WTSLA, ARAY, FSC, SREV Feb 19 2013 
Weekly CFO Buys Highlight: POL, ARAY, ZBB, CRMD, VRX Dec 19 2011 
Accuray Inc. (ARAY) President & CEO Euan Thomson sells 12,500 Shares Mar 11 2011 
Accuray Inc. (ARAY) SVP COO Chris Raanes sells 1,000 Shares Mar 07 2011 

More From Other Websites
ACCURAY INC Files SEC form 10-K, Annual Report Aug 24 2016
ETF’s with exposure to Accuray, Inc. : August 22, 2016 Aug 22 2016
Accuray, Inc. :ARAY-US: Earnings Analysis: Q4, 2016 By the Numbers : August 19, 2016 Aug 19 2016
Accuray, Inc. breached its 50 day moving average in a Bearish Manner : ARAY-US : August 19, 2016 Aug 19 2016
Accuray (ARAY) Stock Sharply Lower After Q4 Results, Guidance Aug 18 2016
Accuray (ARAY) Q4 Loss Wider than Expected, Stock Down Aug 18 2016
Edited Transcript of ARAY earnings conference call or presentation 17-Aug-16 8:30pm GMT Aug 18 2016
Will Accuray (ARAY) Stock Fall on Q4 Miss, Downbeat Outlook? Aug 17 2016
Accuray Inc Earnings Call scheduled for 4:30 pm ET today Aug 17 2016
Accuray reports 4Q loss Aug 17 2016
Accuray reports 4Q loss Aug 17 2016
Accuray Reports Fourth Quarter and Fiscal 2016 Financial Results Aug 17 2016
ACCURAY INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 17 2016
Accuray Reports Fourth Quarter and Fiscal 2016 Financial Results Aug 17 2016
Q4 2016 Accuray Inc Earnings Release - After Market Close Aug 17 2016
Accuray Expands Product Portfolio, Radixact Now CE-Marked Aug 12 2016
Accuray CE Marks its New Radixact™ System Aug 09 2016
Accuray CE Marks its New Radixact™ System Aug 09 2016
New Data Show InCise™ Multileaf Collimator for the CyberKnife® M6™ System may Expand Patient... Aug 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)